Elanco Animal Health Announced The FDA Completed Its Review Of All Major And Minor Technical Sections For Credelio Quattro, And Final 60-day Administrative Review Is Underway, Company's Broad Spectrum Parasiticide On-Track For October US Approval And First Quarter 2025 Launch
Portfolio Pulse from Benzinga Newsdesk
Elanco Animal Health announced that the FDA has completed its review of all major and minor technical sections for Credelio Quattro, a broad-spectrum parasiticide. The final 60-day administrative review is underway, with US approval expected in October and a launch planned for Q1 2025.
August 20, 2024 | 10:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elanco Animal Health is nearing FDA approval for Credelio Quattro, a broad-spectrum parasiticide. The FDA has completed its review, and the final administrative review is underway. Approval is expected in October, with a launch in Q1 2025.
The completion of the FDA's review process and the expected approval of Credelio Quattro is a positive development for Elanco. This could lead to increased revenue from the new product, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100